Page last updated: 2024-12-06

bicozamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bicozamycin is a natural product that has shown promising antifungal activity against various fungal species, including Candida albicans and Aspergillus fumigatus. It was originally isolated from the fungus *Penicillium bicozamycin* and has a complex chemical structure. The compound is known to inhibit the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to cell death. Research into bicozamycin focuses on its potential as a novel antifungal drug, especially for drug-resistant fungal infections. Current studies explore its mechanism of action, its efficacy against specific fungal pathogens, and its potential toxicity. The synthetic accessibility of bicozamycin is being investigated, aiming to develop more efficient and scalable production methods.'

bicozamycin : A commercially important azabicyclic antibiotic obtained from Streptomyces sapporonensis. It inhibits the Rho protein of E. coli. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65807
CHEMBL ID1231250
CHEBI ID60584
MeSH IDM0082783

Synonyms (36)

Synonym
cgp-3543
CHEMBL1231250
cgp-3543/e
bacteron
(1s,6r)-6-hydroxy-5-methylidene-1-[(1s,2s)-1,2,3-trihydroxy-2-methylpropyl]-2-oxa-7,9-diazabicyclo[4.2.2]decane-8,10-dione
bdbm22600
nsc 180516
antibiotic 5879
ws-4545
bicozamycinum [inn-latin]
einecs 253-795-3
fr 1881
(1r*,6s*)-6-hydroxy-5-methylene-1-((1r*,2r*)-1,2,3-trihydroxy-2-methylpropyl)-2-oxa-7,9-diazabicyclo(4.2.2)decan-8,10-dione
aizumycin
bacfeed
bicozamycine [inn-french]
bicozamicina [inn-spanish]
bicozamycin [inn]
cgp 354e
ws 4545
antibiotic ws 4545
bicozamycin
bicozamycinum
bicozamicina
CHEBI:60584 ,
bicozamycine
j03u9e2p82 ,
unii-j03u9e2p82
bicozamycin [jan]
(1s,6r)-6-hydroxy-5-methylene-1-((1s,2s)-1,2,3-trihydroxy-2-methylpropyl)-2-oxa-7,9-diazabicyclo(4.2.2)decane-8,10-dione
ws-4545 antibiotic
bicyclomycin [mi]
bicozamycin [mart.]
8,10-diaza-6-hydroxy-5-methylene-1-(2-methyl-1,2,3-trihydroxypropyl)-2-oxabicyclo(4.2.2)decan-7,9-dione
Q27104872
AKOS040747971

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The plasma concentration was determined on days 1 and 7 of the dosing period."( Plasma concentrations and tissue residues of bicozamycin given orally to pigs.
Hamamoto, S; Ishihara, Y; Yoshimura, H, 1995
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antidiarrhoeal drugAny drug found useful in the symptomatic treatment of diarrhoea.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
azabicycloalkane
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (19.18)18.7374
1990's15 (20.55)18.2507
2000's26 (35.62)29.6817
2010's16 (21.92)24.3611
2020's2 (2.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.83 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.41%)5.53%
Reviews1 (1.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other69 (93.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]